 | Up a level |
2023
Seufferlein, T., Uhl, W., Kornmann, M., Alguel, H., Friess, H., Koenig, A., Ghadimi, M., Gallmeier, E., Bartsch, D. K., Lutz, M. P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C. C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., Waldschmidt, D., Bruns, C., Wittel, U., Fichtner-Feigl, S., Daum, S., Hinke, A., Blome, L., Tannapfel, A., Kleger, A., Berger, A. W., Kestler, A. M. R., Schuhbaur, J. S., Perkhofer, L., Tempero, M., Reinacher-Schick, A. C. and Ettrich, T. J. (2023). Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)da randomized phase II trial of the AIO pancreatic cancer group. Ann. Oncol., 34 (1). S. 91 - 101. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2013
Bludau, M., Hoelscher, A. H., Vallboehmer, D., Metzger, R., Bollschweiler, E. and Schroeder, W. (2013). Vascular endothelial growth factor expression following ischemic conditioning of the gastric conduit. Dis. Esophagus, 26 (8). S. 847 - 853. CARY: OXFORD UNIV PRESS INC. ISSN 1442-2050
Odenthal, M., Bollschweiler, E., Grimminger, P. P., Schroeder, W., Brabender, J., Drebber, U., Hoelscher, A. H., Metzger, R. and Vallboehmer, D. (2013). MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response. Int. J. Cancer, 133 (10). S. 2454 - 2464. HOBOKEN: WILEY-BLACKWELL. ISSN 0020-7136
2012
Vallboehmer, D., Bollschweiler, E., Brabender, J., Wedemeyer, I., Grimminger, P. P., Metzger, R., Schroeder, W., Gutschow, C., Hoelscher, A. H. and Drebber, U. (2012). Evaluation of histological regression grading systems in the neoadjuvant therapy of rectal cancer. Int. J. Colorectal Dis., 27 (10). S. 1295 - 1302. NEW YORK: SPRINGER. ISSN 0179-1958